I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
I wholeheartedly concur! The current trajectory appears...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.34 |
Change
1.140(5.64%) |
Mkt cap ! $2.725B | |||
| Open | High | Low | Value | Volume |
| $20.30 | $21.65 | $20.11 | $14.34M | 673.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 633 | $21.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.34 | 2000 | 2 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.37 |
Change
1.140 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $20.26 | $21.64 | $20.19 | 136487 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| NEU (ASX) Chart |